<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="190422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614211</url>
  </required_header>
  <id_info>
    <org_study_id>LACC001</org_study_id>
    <nct_id>NCT00614211</nct_id>
  </id_info>
  <brief_title>Laparoscopic Approach to Cervical Cancer</brief_title>
  <acronym>LACC</acronym>
  <official_title>A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queensland Centre for Gynaecological Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queensland Centre for Gynaecological Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the long-term outcomes of different
      surgical methods for the treatment of cervical cancer. The long-term outcome of a total
      abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study,
      the laparoscopy will be done with or without robotic technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To compare disease-free survival amongst patients who undergo a total laparoscopic (TLRH) or
      robotic radical hysterectomy (TRRH) verses those who undergo a total abdominal radical
      hysterectomy (TARH) for early stage cervical cancer.

      Secondary Objectives:

        -  Compare patterns of recurrence between arms.

        -  Compare treatment-associated morbidity within 6 months from surgery.

        -  Compare the cost effectiveness of TLRH/TRRH versus TARH

        -  Compare the impact on Quality of Life (QOL) between arms.

        -  Assess pelvic floor function

        -  Compare overall survival between arms

        -  Determine the feasibility of sentinel lymph node biopsy in this group of patients

      RATIONALE FOR STUDY DESIGN Total abdominal radical hysterectomy (TARH) and pelvic lymph node
      dissection (± aortic lymph node dissection ± postoperative [chemo-] radiotherapy) is the
      current standard treatment for early cervical cancer. While this is an accepted effective
      treatment, a laparotomy is highly invasive, visibly scarring and is associated with tissue
      trauma, blood loss and a significant risk of wound and infectious adverse events .
      Additionally, radical hysterectomy by laparotomy is associated with an average hospital stay
      of approximately 5 to 7 days and an average recovery period (from surgery) of 5 to 6 weeks.

      Laparoscopic techniques have been demonstrated to be feasible and safe with previous
      retrospective studies on TLH showing encouraging results . In a number of retrospective and
      prospective, non-controlled series the incidence of treatment-related morbidity was less in
      patients who had a laparoscopic hysterectomy compared to patients who underwent a TAH .
      Retrospective data suggest that the recurrence rate and patterns of recurrence are similar
      in patients who had a laparoscopic or an open approach .

      Treatment recommendations ideally are based on prospective, randomized trials comparing the
      current standard technique (TARH) with the proposed better technique (TLRH). However, there
      are currently no prospective studies available which directly compare TLRH against the
      standard treatment of TARH in regards to disease-free or overall survival.

      The proposed clinical trial will be biphasic. The primary outcome variable in stage 1 will
      be feasibility of recruitment as determined by overall trial recruitment. Following
      completion of Stage 1, the data of this study will become the basis for assessing recurrence
      and disease-free survival in the Stage 2 design.

      RATIONALE FOR THE QUALITY OF LIFE Retrospective studies suggest equivalency between the
      laparoscopic and open approaches to radical hysterectomy in regards to surgical specimens
      obtained and likely disease-free and overall survivals . Thus, quality of life could be seen
      as one of the most significant factors in recommending one approach over the other and
      therefore an extremely important endpoint for this protocol. In the GOG LAP-2 protocol , a
      trial evaluating a comparison between hysterectomy by laparotomy or laparoscopy, the
      investigators found equivalency adequacy of the two surgical approaches however a
      significant difference in short term quality of life favoring laparoscopy. As expected,
      patients who underwent laparoscopy had a faster return to baseline functioning compared with
      those patients who had undergone laparotomy which translated into improved short-term
      quality of life. By 6 months, however, patients in both cohorts were reporting equivalent
      quality of life parameters. Quality of life surveys employed with this Phase III clinical
      trial will encompass important endpoints such as postoperative pain and related symptoms
      using the MD Anderson Symptom Assessment Index (MDSAI), as well as cancer specific
      Functional Assessment of Cancer Therapy (FACT-Cx) and the general 12-Item Short-Form Health
      Survey (SF-12).

      RATIONALE FOR LYMPHATIC MAPPING Published experience with the techniques for lymphatic
      mapping and sentinel lymph node detection in women with cervical cancer has been very
      limited. To date, no single study has enrolled more than 100 patients undergoing lymphatic
      mapping as part of their surgical treatment for cervical cancer. In fact, the majority of
      studies report on less than 50 patients. In addition, this procedure has not yet been shown
      to be viable in a multi-institutional setting. The limitations of previously published
      reports are important as these techniques are associated with a significantly high learning
      curve with early procedures less successful than later ones. This study will provide us the
      opportunity to enroll large numbers of patients for validation of intraoperative lymphatic
      mapping in women with cervical cancer in an international, multi-institutional setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years from surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of recurrence</measure>
    <time_frame>5 years from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>6 months from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory</measure>
    <time_frame>5 years from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of sentinel lymph node biopsy</measure>
    <time_frame>Intra-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative, peri-operative, post-operative and long term treatment related morbidity</measure>
    <time_frame>6 months from surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Abdominal Radical Hysterectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Laparoscopic or Robotic Radical Hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Abdominal Radical Hysterectomy</intervention_name>
    <description>In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TARH</other_name>
    <other_name>Open radical hysterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Laparoscopic or Robotic Radical Hysterectomy</intervention_name>
    <description>In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>TLRH</other_name>
    <other_name>TRRH</other_name>
    <other_name>Keyhole radical hysterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or
             adenosquamous carcinoma of the uterine cervix;

          -  Patients with Histologically confirmed stage IA1 (with lymph vascular invasion),
             stage IA2, or stage IB1 disease

          -  Patients undergoing either a Type II or III radical hysterectomy (Piver
             Classification)

          -  Patients with adequate bone marrow, renal and hepatic function:

          -  ECOG Performance Status of 0 or 1.

          -  Patient must be suitable candidates for surgery.

          -  Patients who have signed an approved Informed Consent

          -  Patients with a prior malignancy allowed if &gt; 5 years ago with no current evidence of
             disease

          -  Females, aged 18 years or older

          -  Negative serum pregnancy test within &lt;30 days of surgery in pre-menopausal women and
             women &lt; 2 years after the onset of menopause

        Exclusion Criteria:

          -  Any histology other than adenocarcinoma, squamous cell carcinoma or adenosquamous
             carcinoma of the uterine cervix;

          -  Tumor size greater than 4 cm;

          -  FIGO stage II-IV;

          -  Patients with a history of pelvic or abdominal radiotherapy;

          -  Patients who are pregnant;

          -  Patients with contraindications to surgery;

          -  Patients with evidence of metastatic disease by conventional imaging studies,
             enlarged pelvic or aortic lymph nodes &gt; 2cm; or histologically positive lymph nodes

          -  Unfit for Surgery: serious concomitant systemic disorders incompatible with the study
             (at the discretion of the investigator);

          -  Patients unable to withstand prolonged lithotomy and steep Trendelenburg position

          -  Patient compliance and geographic proximity that do not allow adequate follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Ramirez, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Obermair, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Queensland Centre for Gynecological Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Frumovitz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Behan, BNursing</last_name>
    <phone>+61 7 3646 4343</phone>
    <email>Vanessa.Behan@health.qld.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pedro Ramirez</last_name>
    <email>peramire@mdanderson.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greater Baltimore Medical Centre</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Fader, MD</last_name>
      <email>amandanfader@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Amanda Fader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Centre Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Spirtos, MD</last_name>
      <email>nspirtos@wccenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Farzana Siddiqui</last_name>
      <email>drfarzana313@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nick Spirtos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Luke's - Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Oklahoma Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Walker, MD</last_name>
      <email>Joan-Walker@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Chaney</last_name>
      <email>Stephhanie-Chaney@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joan Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndon B. Johnson - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Ramirez, M.D.</last_name>
      <email>peramire@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Melendez</last_name>
      <email>cvmelend@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Ramirez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anuja Jhingran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela T Soliman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles F Levenback, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen M Schmeler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael T Deavers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jubilee Brown</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Westin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alpa Nick</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Misericordia Hospital</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernado Larrazabal</last_name>
      <email>flarrazabal@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Carolina Bedoya</last_name>
      <email>caro_3393@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Larrazabal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucio Bedoya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Behan</last_name>
      <phone>+61 7 3646 4343</phone>
      <email>Vanessa.Behan@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+61 7 3646 0447</phone>
      <email>Trudi.Cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Russell Land, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Nicklin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Behan, Bach Nursing</last_name>
      <phone>+61 7 3646 4343</phone>
      <email>Vanessa.Behan@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+61 7 3646 0447</phone>
      <email>Trudi.Cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Obermair, MD FRANZCOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Land, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Behan, BNursing</last_name>
      <phone>+61 7 3646 4343</phone>
      <email>Vanessa.Behan@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+61 7 3646 0447</phone>
      <email>Trudi.Cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Obermair, MD, FRANZCOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Land, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Nicklin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Health Services</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Behan</last_name>
      <phone>+61 7 3646 4343</phone>
      <email>Vanessa.Behan@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Naven Chetty</last_name>
      <email>navenchetty@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Naven Chetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lewis Perrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Behan</last_name>
      <phone>+61 7 3646 4343</phone>
      <email>Vanessa.Behan@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+ 61 7 3646 0447</phone>
      <email>trudi.cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Obermair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Land, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Nicklin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naven Chetty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lewis Perrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John of God</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raj Ganendra, MD</last_name>
      <email>Raj.ganendra@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Jeffares</last_name>
      <email>Stephanie.Jeffares@sjog.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Raj Ganendra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yee Leung, MD</last_name>
      <email>Yee.Leung@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Paul Cohen, MD</last_name>
      <email>Paul.Cohen@health.wa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Yee Leung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John of God</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Cohen, MD</last_name>
      <email>Paul.Cohen@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Jeffares</last_name>
      <email>Stephanie.Jeffares@sjog.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Salfinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Tan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raj Ganendra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erastus Gaertner Hospital</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reitan Ribeiro</last_name>
      <email>reitanribeiro@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nathalia Carneiro</last_name>
      <email>nathalia.kolb@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reitan Ribeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey Tsunoda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Hospital</name>
      <address>
        <city>Morumbi</city>
        <state>San Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Assir</last_name>
      <email>fernanda.assir@einstein.br</email>
    </contact>
    <contact_backup>
      <last_name>Mariano Tamura, MD</last_name>
      <email>mariano.tamura@einstein.br</email>
    </contact_backup>
    <investigator>
      <last_name>Mariano Tamura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controlle do Cancer</name>
      <address>
        <city>Bras</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Mauri</last_name>
      <email>julianomauri@ibcc.org.br</email>
    </contact>
    <contact_backup>
      <last_name>Josiane Pesquisa</last_name>
      <email>josiane.pesquisa@ibcc.org.br</email>
    </contact_backup>
    <investigator>
      <last_name>Gabriel Lowndes de S Pinto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Humberto</last_name>
      <email>mdfregnani@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Julio Nap</last_name>
      <email>julio.nap@hcancerbarretos.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Humberto</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcello Vieira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Andrade, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Pleven Center of Oncology Gynaecology</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grigor Gorchev, MD</last_name>
      <email>oncogynec@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Grigor Gorchev</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slavcho Tomov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Bernardini</last_name>
      <email>marcus.bernardini@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Aysha Zia</last_name>
      <email>Aysha.Zia@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marcus Bernardini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Dodge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barry Rosen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affilated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhu, MD</last_name>
      <email>kernor@163.com</email>
    </contact>
    <investigator>
      <last_name>Tao Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojian Yan</last_name>
      <email>yxjbetter@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaojian Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-qin Zhao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institito De Cancerologia Clinica Las Americas</name>
      <address>
        <city>Antioquia</city>
        <state>Medellin</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute and Research Center</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupinder Sekhon</last_name>
      <email>rupysekhon@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rupinder Sekhon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alessandro Manzoni Hospital</name>
      <address>
        <city>Lecco</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pellegrino</last_name>
      <email>dr.pellierino@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Mario Villa, MD</last_name>
      <email>m.villa@ospedale.lecco.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Pellegrino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Buda</last_name>
      <email>alessandro.buda@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Buda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Signorelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart</name>
      <address>
        <city>Milan</city>
        <state>Rome</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Capobianco</last_name>
      <email>francesca.capobianco@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Anna Fagotti, MD</last_name>
      <email>anna.fagotti@zm.unicatt.it</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Fagotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Consentino Frances, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Cirrarone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Boveri</last_name>
      <email>sara.boveri@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Angelo Maggioni, MD</last_name>
      <email>angelo.maggioni@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Angelo Maggioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanna Zanagnolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Landoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Centre, CHA University</name>
      <address>
        <city>Bundang</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gangnam CHA Medical Centre</name>
      <address>
        <city>Gangnam-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre</name>
      <address>
        <city>Gangnam-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Hospital</name>
      <address>
        <city>Mok-dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Young Ryu</last_name>
      <email>ryu@kcch.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jung-Yeob Seoung</last_name>
      <email>sjyeob@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sang-Young Ryu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Centre</name>
      <address>
        <city>Songpa-Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, MD</last_name>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sookin Kwon</last_name>
      <email>sookin76@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Joo-Hyun Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeong-Yeol Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong-Hyeok Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dae-Yeon Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Tak Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Man Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University - Department of Obstetrics and Gynecology</name>
      <address>
        <city>Yeongeon-dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Weon Kim, MD</last_name>
      <email>kjwksh@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae-Weon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cencerologia</name>
      <address>
        <city>Tlalpan</city>
        <state>Mexico City</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Nava</last_name>
      <email>Ichigo_mind@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>David Isla Ortiz, MD</last_name>
      <email>islasurgery@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Isla Ortiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <state>Surquillo</state>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ninoska Macavilca</last_name>
      <email>nmacavilca@inen.sld.pe</email>
    </contact>
    <contact_backup>
      <last_name>Aldo Lopez</last_name>
      <email>aldolopezmd77@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aldo Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Franco Valdivia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Alvarez Larraondo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Velarde Navarrete, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Sanchez Salledo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Absalon Montoya Guivin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Zevalos Cardenas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladamir Villoslada Terrones, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Marrufo Avellaneda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyneco-Oncologico Hospital HIMA</name>
      <address>
        <city>Caguas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Escobar</last_name>
      <email>escobarp@mac.com</email>
    </contact>
    <contact_backup>
      <last_name>Wilma Gonzalez</last_name>
      <email>wlima.gonzalez@upr.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <link>
    <url>http://www.gyncan.org/</url>
    <description>QCGC Research</description>
  </link>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Cancer Treatment and Research Centre</description>
  </link>
  <reference>
    <citation>Obermair A, Gebski V, Frumovitz M, Soliman PT, Schmeler KM, Levenback C, Ramirez PT. A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer. J Minim Invasive Gynecol. 2008 Sep-Oct;15(5):584-8. doi: 10.1016/j.jmig.2008.06.013.</citation>
    <PMID>18722970</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 23, 2016</lastchanged_date>
  <firstreceived_date>January 31, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix</keyword>
  <keyword>Cervical</keyword>
  <keyword>Cancer</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Radical hysterectomy</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Robotic</keyword>
  <keyword>Squamous Cell</keyword>
  <keyword>Adenosquamous</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Lymphatic Mapping</keyword>
  <keyword>IOLM</keyword>
  <keyword>SPECT</keyword>
  <keyword>Sentinel Node</keyword>
  <keyword>Uterine cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
